ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models

Advances in oral SERDs development so far have been confined to nonsteroidal molecules such as those containing a cinnamic acid moiety, which are in earlystage clinical evaluation. ZB716 was previously reported as an orally bioavailable SERD structurally analogous to fulvestrant. In this study, we e...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Guo, Shanchun, Zhang, Changde, Bratton, Melyssa, Mottamal, Madhusoodanan, Liu, Jiawang, Ma, Peng, Zheng, Shilong, Zhong, Qiu, Yang, Lin, Wiese, Thomas E., Wu, Yong, Ellis, Matthew J., Matossian, Margarite, Burow, Matthew E., Miele, Lucio, Houtman, René, Wang, Guangdi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805526/
https://ncbi.nlm.nih.gov/pubmed/29467940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24023
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia